Lewis E. Braverman

Lewis E. Braverman (March 30, 1929 June 10, 2019) was a U.S. endocrinologist who specialized in thyroid gland problems. He discovered that humans converted thyroxine to triiodothyronine. He was a mentor to physicians for over 40 years.

Lewis E. Braverman
Born(1929-03-30)March 30, 1929
Boston, Massachusetts, US
DiedJune 10, 2019(2019-06-10) (aged 90)
Boston, Massachusetts, US
NationalityAmerican
OccupationMedical doctor
Known forDiscovery that humans convert thyroxine to triiodothyronine
Amiodarone-induced thyroid dysfunction
Work on thyrotoxicosis factitia; environmental pollutants as endocrine disruptors
Medical career
InstitutionsTufts St Elizabeth's Hospital, Boston
University of Massachusetts Medical Center
Boston University
Sub-specialtiesEndocrinology
ResearchStudy of thyroid hormone

Early life and education

Lewis E. Braverman was born in Boston on March 30, 1929[1] where his father was a general practitioner and his mother helped run the practice. He grew up in Quincy, Massachusetts. He attended Harvard College, graduated in 1951, and then went to Johns Hopkins University School of Medicine, graduating MD in 1955.[2]

Career

Braverman was an intern at Beth Israel Hospital in Boston. Thereafter he served for two years in the U.S. military in France under the Berry Plan. He returned to the United States for an internal medicine residency at Boston City Hospital, and trained with the director of the Thorndike Memorial Laboratory.[2]

From 1962 to 1975 Braverman was chief of endocrinology at Tufts University School of Medicine St Elizabeth's Hospital, and from 1975 to 1998 at the University of Massachusetts Medical Center. From 1999 until retirement in 2017, he was chief of endocrinology at Boston University.[2]

Work and legacy

Braverman discovered that thyroid hormone is metabolized to triiodo-L-thyronine (T3) in tissues outside the thyroid gland in humans, and published this in 1970 with his colleagues Sidney H. Ingbar and Kenneth Sterling.[3]

He found the cause of a 1984 outbreak of thyrotoxicosis in Minnesota, South Dakota, and Iowa was ground beef contaminated with tissue from the animals' thyroid glands.[2][4]

Braverman is also credited with the discovery that the heart drug amiodarone was one of the most common causes of iodine-induced thyrotoxicosis, a finding which he published, with others, in 1985.[5]:2425[6]

Personal life

He was married and had two sons, Daniel and William Braverman.[7] He died from Waldenström macroglobulinemia on June 10, 2019, aged 90 years.[2]

gollark: So that you don't have a billion different peripherals in a drone.
gollark: It's good that you actually get to customise stuff.
gollark: Okay, the components:I like those myself.
gollark: Citation: OPPM, ocd.cil.li
gollark: OC has lots of documentation, and vast software libraries which are *actually good* and not just "OS"es.

References

  1. "Directory". American College of Physicians. 1973. Retrieved August 26, 2019.
  2. Marcus, Adam (August 3, 2019). "Lewis E Braverman". The Lancet. 394 (10196): 378. doi:10.1016/S0140-6736(19)31673-3. ISSN 0140-6736.
  3. Braverman, Lewis E.; Ingbar, Sidney H.; Sterling, Kenneth (May 1, 1970). "Conversion of Thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects". Journal of Clinical Investigation. 49 (5): 855–864. doi:10.1172/JCI106304. ISSN 0021-9738. PMC 535757. PMID 4986007.
  4. "Lewis E. Braverman." Interview by Michael Chappelle. Oral and Video History Interviews. The Endocrine Society, June 22, 2014. Web. October 2, 2016.
  5. Martino, E.; Aghini-Lombardi, F.; Lippi, F.; Baschieri, L.; Safran, M.; Braverman, L. E.; Pinchera, A. (1985). "Twenty-four hour radioactive iodine uptake in 35 patients with amiodarone associated thyrotoxicosis". Journal of Nuclear Medicine. 26 (12): 1402–1407. ISSN 0161-5505. PMID 4067643.
  6. ATA History – Lewis Braverman on what made him interested in thyroidology American Thyroid Association. October 2015
  7. "Lewis E. Braverman, MD". American Thyroid Association. June 13, 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.